Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Infectious Disease Model Development Service
Are you currently facing complex challenges in pre-clinical studies, such as finding a relevant model that accurately mimics human disease progression? Our Nonhuman Primate (NHP) Infectious Diseases Model Development service helps you accelerate vaccine and therapeutic development by providing robust and translational disease models. We achieve this through advanced nonhuman primate research platforms and a deep understanding of host-pathogen interactions.
Overview of NHP Infectious Diseases Model Development
What Our Service Is
At Creative Biolabs, we specialize in the development and utilization of NHP models for infectious diseases. Our service provides a sophisticated platform for investigating virus-host interactions, evaluating the efficacy and safety of new drug candidates, and accelerating vaccine development. These models are defined by their unparalleled biological and immunological similarity to humans, making them a critical tool when other animal models, such as mice, fail to replicate human-like disease pathologies. Our services are essential for a variety of critical research applications, including:
- Vaccine Efficacy Studies: Evaluating the immune response and protective capabilities of novel vaccine candidates against pathogens like HIV, influenza, and SARS-CoV-2.
- Therapeutic Drug Testing: Assessing the in vivo efficacy and pharmacokinetics of antiviral drugs and immunomodulatory therapies.
- Pathogenesis and Transmission Research: Investigating the mechanisms of disease progression and transmission, including congenital and respiratory infections.
Why Choose Us?
The value we create for our clients is rooted in overcoming the significant pain points in pre-clinical research. The long timelines and high costs associated with finding a relevant translational model can delay market entry. Our services address this by providing a reliable and predictive platform, giving you confidence in your data and accelerating your path to clinical trials. The close phylogenetic and physiological similarities between NHPs and humans ensure that data generated in our models is highly translatable, reducing the risk of failure in later stages of development. We provide the expertise, resources, and robust data you need to make informed decisions and secure your next research milestone.
Fig.1 Viral disease infection models in pediatric NHPs.1
Key Benefits of Our Service
Creative Biolabs' NHP infectious disease models offer a distinct advantage over alternative platforms. Our commitment to scientific excellence and operational efficiency ensures you receive high-quality, actionable data.
- Speed & Responsiveness: We understand that time is of the essence in drug discovery. Our streamlined project management and dedicated team ensure a fast turnaround from study design to final data delivery, helping you maintain momentum in your research.
- Access to Premium NHP Resources: We maintain a robust and well-managed colony of rhesus and cynomolgus macaques. Our facilities and staff adhere to the highest ethical standards and the "Three Rs" (Replacement, Reduction, and Refinement) to provide a reliable supply of animals for your research needs.
- Customization: Every project is unique. We provide fully customizable study designs, from inoculation routes and viral strains to sample collection timelines and data endpoints, to perfectly align with your specific research objectives.
- Reporting Depth: Our final reports go beyond raw data. We provide comprehensive data analysis, detailed model annotations, and expert interpretation to help you understand the full context of your results.
How Creative Biolabs' NHP Model Development Can Assist Your Project?
Our services are designed to provide a clear, step-by-step solution to your pre-clinical challenges. We offer a transparent and collaborative workflow that ensures you are informed and in control at every stage.
01
Required Starting Materials
02
Project Consultation & Study Design
03
Animal Procurement & Acclimation
04
Inoculation & Dosing
05
Clinical Monitoring & Sample Collection
06
End-of-Study Analysis & Reporting
Key Deliverables
- Comprehensive final study report
- Raw data (including viral load, antibody titers, cytokine profiles, etc.)
- Digital images and histopathological slides
- Model annotations and detailed procedural logs
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: Over 50,000 samples analyzed per year.
- Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
- Study Pass Rate: 99%+ success rate in meeting study endpoints.
Our Valued Partners
Frequently Asked Questions
Q: Why use NHP models when there are so many other options like mice or ferrets?
A: While other models have their place, NHPs are often the only choice for complex human diseases. Their close genetic and immunological makeup ensures that a drug or vaccine's effects and a disease's progression will be more accurately reflected, giving you more confidence in your results. To learn more about how our models can specifically address your unique research questions, please contact our team for a consultation.
Q: What specific diseases can you model with your NHP services?
A: We have well-established models for a range of human pathogens, including SARS-CoV-2, influenza, HIV, Zika, and respiratory syncytial virus. Our flexibility allows us to develop and validate custom models for emerging or novel pathogens as well. We would be happy to discuss your specific needs in more detail.
Q: How do you ensure the data I get is of the highest quality?
A: We employ state-of-the-art laboratory techniques and a rigorous quality control program. Our team consists of experienced veterinarians and scientists who meticulously monitor every step of the study. Each project is managed by a dedicated project manager who ensures all aspects of the study protocol are meticulously followed, resulting in reliable and reproducible data.
Q: How does your process compare to developing a model in-house?
A: Developing a new model in-house can be incredibly resource-intensive and time-consuming. By partnering with us, you gain immediate access to established models, our state-of-the-art facilities, and a team of experts, saving you significant time and money while ensuring the highest level of scientific rigor.
Contact Us
Creative Biolabs is your trusted partner in accelerating pre-clinical infectious disease research. Our expertise in NHP model development, combined with our commitment to scientific excellence and customer service, provides an unparalleled value for your projects. To discuss your specific project needs and learn how our NHP infectious diseases models can help you achieve your goals, please reach out to our team today.
Reference
- Vijayan KK, Vidya, and Kristina De Paris. "Nonhuman primate models of pediatric viral diseases." Frontiers in Cellular and Infection Microbiology 14 (2024). Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.3389/fcimb.2024.1493885